Aponvie™ (aprepitant) has been made available by Heron Therapeutics for the prevention of postoperative nausea and vomiting in adults.
Aponvie is an injectable emulsion formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. The formulation is identical to Heron’s approved drug product Cinvanti®, which is indicated for chemotherapy-induced nausea and vomiting.
The safety and efficacy of Aponvie were established based on adequate and well-controlled studies of a single-dose of oral aprepitant in adults. Additionally, a single 32 mg dose of Aponvie was found to be bioequivalent to oral aprepitant 40 mg in a phase 1 study.
Aponvie is supplied in a single-dose vial containing 32 mg of aprepitant.
This article originally appeared on MPR
- Heron Therapeutics announces US commercial launch of Aponvie™ for the management of postoperative nausea and vomiting in adults. News release. Heron Therapeutics. March 6, 2023. https://www.prnewswire.com/news-releases/heron-therapeutics-announces-us-commercial-launch-of-aponvie-for-the-management-of-postoperative-nausea-and-vomiting-in-adults-301763277.html.
- Aponvie. Package insert. Heron Therapeutics; 2022. Accessed March 6, 2023. https://aponvie.com/prescribing-information.pdf.